Overview

Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The efficacy and safety are evaluated when YAM80 is administered orally to the patients of Amyotrophic Lateral Sclerosis (ALS).
Phase:
Phase 2
Details
Lead Sponsor:
Yoshino Neurology Clinic